Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis
Background: Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases. Objectives: To investigate effectiveness and tolerability of oral MMF in adult pa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1468068 |
| _version_ | 1797683739971551232 |
|---|---|
| author | David Dias-Polak Reuven Bergman Emily Avitan-Hersh |
| author_facet | David Dias-Polak Reuven Bergman Emily Avitan-Hersh |
| author_sort | David Dias-Polak |
| collection | DOAJ |
| description | Background: Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases. Objectives: To investigate effectiveness and tolerability of oral MMF in adult patients with severe recalcitrant AD. Methods: During the years 2010–2017 oral MMF 2–3 g/day was administered to adult patients with severe recalcitrant AD who failed other major systemic drugs, or where other drugs, including cyclosporine (CSA), methotrexate, and azathioprine, were contraindicated. Results: Of 9 consecutive adult patients, 4 (44%) responded completely, 2 (22%) had partial response, and 3 (33%) did not respond at all. The MMF therapy was continued for 5–36 months (average 21 months) without major side effects. Conclusions: Oral MMF may be an effective drug in AD. Due to its good safety profile, it may be recommended as a first-line systemic therapy, or successive to CSA in the long term. |
| first_indexed | 2024-03-12T00:19:07Z |
| format | Article |
| id | doaj.art-5d0d95c9f5144eea8da689071f57cb6d |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:07Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5d0d95c9f5144eea8da689071f57cb6d2023-09-15T14:08:32ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532019-01-01301495110.1080/09546634.2018.14680681468068Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitisDavid Dias-Polak0Reuven Bergman1Emily Avitan-Hersh2Technion - Israel Institute of TechnologyTechnion - Israel Institute of TechnologyTechnion - Israel Institute of TechnologyBackground: Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases. Objectives: To investigate effectiveness and tolerability of oral MMF in adult patients with severe recalcitrant AD. Methods: During the years 2010–2017 oral MMF 2–3 g/day was administered to adult patients with severe recalcitrant AD who failed other major systemic drugs, or where other drugs, including cyclosporine (CSA), methotrexate, and azathioprine, were contraindicated. Results: Of 9 consecutive adult patients, 4 (44%) responded completely, 2 (22%) had partial response, and 3 (33%) did not respond at all. The MMF therapy was continued for 5–36 months (average 21 months) without major side effects. Conclusions: Oral MMF may be an effective drug in AD. Due to its good safety profile, it may be recommended as a first-line systemic therapy, or successive to CSA in the long term.http://dx.doi.org/10.1080/09546634.2018.1468068atopic dermatitisrecalcitrantmycophenolate mofetil |
| spellingShingle | David Dias-Polak Reuven Bergman Emily Avitan-Hersh Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis Journal of Dermatological Treatment atopic dermatitis recalcitrant mycophenolate mofetil |
| title | Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| title_full | Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| title_fullStr | Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| title_full_unstemmed | Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| title_short | Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| title_sort | mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis |
| topic | atopic dermatitis recalcitrant mycophenolate mofetil |
| url | http://dx.doi.org/10.1080/09546634.2018.1468068 |
| work_keys_str_mv | AT daviddiaspolak mycophenolatemofetiltherapyinadultpatientswithrecalcitrantatopicdermatitis AT reuvenbergman mycophenolatemofetiltherapyinadultpatientswithrecalcitrantatopicdermatitis AT emilyavitanhersh mycophenolatemofetiltherapyinadultpatientswithrecalcitrantatopicdermatitis |